ozekibart

Other

Filedunder review

Evidence outlook · regulatory review

Conventional Chondrosarcoma: application under FDA review, decision date 2027-04-14

FDA accepts the ozekibart BLA in conventional chondrosarcoma (PDUFA goal date 14 April 2027) (2026-06-15). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

ChonDRAgon (NCT04950075): This was a randomized, quadruple-masked Phase 2 trial with 206 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-10-23. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Featured evidence outside this drug's tracked markets:NCT03715933 · Ewing Sarcoma · Phase 1 · ungraded

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Conventional Chondrosarcoma
Phase 1 (1)
Other / comorbidity
NCT03715933 · Inhibrx Biosciences, Inc
2018-10-08 – 2029-06 · Ewing Sarcoma, Colorectal Adenocarcinoma
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow ozekibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 1Ewing Sarcoma, Colorectal AdenocarcinomaRecruiting
Est. primary completion 2028-12 · NCT03715933 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

14 April 2027FDA action datePDUFA goal date set for April 14, 2027
US, FDA · Source ↗

Recent

15 June 2026Filing acceptedFDA accepts the ozekibart BLA in conventional chondrosarcoma (PDUFA goal date 14 April 2027)
US, FDA · Inhibrx Biosciences, Inc. · Source ↗
23 October 2025Topline resultRegistrational ChonDRAgon trial of ozekibart met its primary endpoint (PFS)
Inhibrx Biosciences, Inc · Source ↗
21 January 2025Topline resultPreliminary Phase 1 data for ozekibart plus FOLFIRI in colorectal cancer